Begin.ai is an Artificial Intelligence start-up that aims to provide B2B2C solutions for mobile AI problems through its innovative AI/ML process for mobile apps. To achieve this, Begin provides mobile app for developers and producers with a no-ML code platform that accelerates AI production by automating the entire machine learning life cycle.

Through their online portal, Callia enables consumers to conveniently and easily send flowers and local small gifts directly to the door of friends and family. Callia has created a unique SaaS platform, with a vertically integrated supply chain, enabling them to work directly with wholesalers and own the customer experience to last mile delivery.

Coloursmith Labs is a tech-enabled optical materials company that is disrupting the potential of modern eyewear with breakthrough optical filtering technology. The company can create endless varieties of novel optical filters in eyeglass and contact lenses. Specifically valuable are the firm's products targeting colour enhancement and hazardous light protection.

DeNova is developing and commercializing a suite of breakthrough technologies that convert harmful greenhouse gases into high-quality protein, disrupting the protein market. DeNova captures GHG emissions, and, using a proprietary, modular conversion technology, converts these waste emissions into the low-cost methanol supply that is the key feedstock for DeNova’s large-scale production of sustainable protein derived from natural bacteria.

Fable Home is an innovative direct-to-consumer brand that is creating minimal, durable, and sustainably designed products for the home. Consumers are provided with artisan-crafted and affordable products designed in Vancouver and crafted in Portugal. Fable offers a simplified selection, cohesive design, seamless customer journey, and a relatable brand.

Gotcare is a healthcare provider transforming how health services are delivered in the home. Their patent-pending technology increases patient access to care and reduces the cost of care delivery. Gotcare employs the community care workers they work with and pays a living wage.

ProcedureFlow is an Enterprise Knowledge Management software designed to help organizations 1) Democratize, visualize, and navigate their processes. 2) Maintain processes through employee crowdsourcing, engagement, and collaboration. 3) Produce in-depth operational reporting and analytics to inform automation and continuous business development.

QuickFacts Inc. has developed a SaaS platform which integrates and displays information from multiple insurance carriers side-by-side, reducing insurance broker search time by 10 to 20 times. Currently, brokers must view multiple password-gated websites and portals to access insurance carrier information. QuickFacts removes this barrier by compiling all the information into a centralized database, allowing users access to all their insurance carrier information with one log-in.

Shoelace is an innovative learning company which has developed a platform to deliver research based and adaptive learning content to players anywhere in the world through hyper-engaging games. The company has developed a unique way for teachers to create and deliver assignments through games.

Siftmed is an AI-enabled platform that transforms medical file processing. Siftmed helps its clients (medical experts, lawyers, and insurance companies) easily find facts so patients can get better outcomes faster using natural language processing and optical character recognition. Siftmed creates a timeline of medical files, categorizes them by type (i.e. MRI, Imaging report) and makes them searchable & smart. Users can tag, create notes, and easily make a report.

Swiftsure Innovations produces Complete Care System for preventing ventilator-associated pneumonia (VAP). The Complete Care System consists of an innovative endotracheal tube (ETT) and a daily oral care kit. The Complete Care System aims to prevent VAP by allowing nurses to conduct proper nasal and oral irrigations. Swiftsure Innovations is patent pending for a Class II (510K) exempt medical device that enables safe oral irrigation of patients receiving critical care.

Simmunome is at the leading edge of leveraging AI towards unraveling biological complexity. Simmunome’s clinical development platform allows users to input preclinical and clinical data to derive disease-specific insights and help clinical R&D researchers make critical go/no-go decisions. By combining multi-omic data to create comprehensive models of disease, Simmunome simulates biological processes to identify novel drug targets and predict and improve clinical outcomes. Using this approach, highly accurate simulations of biological processes can be attained, for more faithful representations and predictions. Ultimately, Simmunome de-risks clinical research, reduces R&D costs and dramatically accelerates health research and innovation.